Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.
Bruel T, Vrignaud LL, Porrot F, Staropoli I, Planas D, Guivel-Benhassine F, Puech J, Prot M, Munier S, Bolland WH, Soulié C, Zafilaza K, Lusivika-Nzinga C, Meledge ML, Dorival C, Molino D, Péré H, Yordanov Y, Simon-Lorière E, Veyer D, Carrat F, Schwartz O, Marcelin AG, Martin-Blondel G; ANRS 0003S CoCoPrev Study Group. Bruel T, et al. Among authors: zafilaza k. Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007. Med. 2023. PMID: 37837962 Free article.
Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers.
Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, Gothland A, Jary A, Dorgham K, Bruel T; Sorbonne Université SARS-CoV-2 Neutralizing Antibodies Study Group; Burrel S, Boutolleau D, Schwartz O, Gorochov G, Calvez V, Marcelin AG. Marot S, et al. Among authors: zafilaza k. Nat Commun. 2021 Feb 8;12(1):844. doi: 10.1038/s41467-021-21111-9. Nat Commun. 2021. PMID: 33558507 Free PMC article.
The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients.
Teyssou E, Soulie C, Visseaux B, Lambert-Niclot S, Ferre V, Marot S, Jary A, Sayon S, Zafilaza K, Leducq V, Schnuriger A, Abdi B, Wirden M, Houhou-Fidouh N, Charpentier C, Morand-Joubert L, Burrel S, Descamps D, Calvez V, Marcelin AG. Teyssou E, et al. Among authors: zafilaza k. J Infect. 2021 Jul;83(1):119-145. doi: 10.1016/j.jinf.2021.04.023. Epub 2021 Apr 28. J Infect. 2021. PMID: 33932451 Free PMC article. No abstract available.
Author Correction: Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers.
Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, Gothland A, Jary A, Dorgham K, Bruel T; Sorbonne Université SARS-CoV-2 Neutralizing Antibodies Study Group; Burrel S, Boutolleau D, Schwartz O, Gorochov G, Calvez V, Marcelin AG. Marot S, et al. Among authors: zafilaza k. Nat Commun. 2021 May 10;12(1):2824. doi: 10.1038/s41467-021-23128-6. Nat Commun. 2021. PMID: 33972561 Free PMC article. No abstract available.
Nosocomial transmission clusters and lineage diversity characterized by SARS-CoV-2 genomes from two large hospitals in Paris, France, in 2020.
Leducq V, Jary A, Bridier-Nahmias A, Daniel L, Zafilaza K, Damond F, Goldstein V, Duval A, Blanquart F, Calvez V, Descamps D, Marcelin AG, Visseaux B. Leducq V, et al. Among authors: zafilaza k. Sci Rep. 2022 Jan 20;12(1):1094. doi: 10.1038/s41598-022-05085-2. Sci Rep. 2022. PMID: 35058525 Free PMC article. Clinical Trial.
Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies.
Jary A, Marot S, Faycal A, Leon S, Sayon S, Zafilaza K, Ghidaoui E, Quoc SN, Nemlaghi S, Choquet S, Dres M, Pourcher V, Calvez V, Junot H, Marcelin AG, Soulié C. Jary A, et al. Among authors: zafilaza k. Viruses. 2022 Jan 24;14(2):226. doi: 10.3390/v14020226. Viruses. 2022. PMID: 35215820 Free PMC article.
Long-term evolution of humoral immune response after SARS-CoV-2 infection.
Teyssou E, Zafilaza K, Sayon S, Marot S, Dropy M, Soulie C, Abdi B, Tubach F, Hausfater P, Marcelin AG, Boutolleau D; SEROCOV study group. Teyssou E, et al. Among authors: zafilaza k. Clin Microbiol Infect. 2022 Jul;28(7):1027.e1-1027.e4. doi: 10.1016/j.cmi.2022.03.012. Epub 2022 Mar 17. Clin Microbiol Infect. 2022. PMID: 35307573 Free PMC article.
High SARS-CoV-2 seroprevalence in HIV patients originating from sub-Saharan Africa in the Ile-de-France area: Seroprevalence of SARS-CoV-2 in HIV patients.
Abdi B, Ndoadoumgue AL, Djebara S, Zafilaza K, Palich R, Marot S, Schneider L, Wirden M, Seang S, Dudoit Y, Teyssou E, Tubiana R, Soulie C, Valantin MA, Katlama C, Calvez V, Assoumou L, Marcelin AG, Pourcher V. Abdi B, et al. Among authors: zafilaza k. J Infect. 2022 Aug;85(2):e33-e36. doi: 10.1016/j.jinf.2022.05.036. Epub 2022 Jun 2. J Infect. 2022. PMID: 35662666 Free PMC article. No abstract available.
High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2.
Pourcher V, Belin L, Soulie C, Rosenzwajg M, Marot S, Lacombe K, Valin N, Pialoux G, Calin R, Palacios C, Malet I, Zafilaza K, Tubiana R, Valantin MA, Klatzmann D, Calvez V, Simon-Tillaux N, Marcelin AG. Pourcher V, et al. Among authors: zafilaza k. AIDS. 2022 Sep 1;36(11):1545-1552. doi: 10.1097/QAD.0000000000003300. Epub 2022 Jun 22. AIDS. 2022. PMID: 35730380
21 results